Roche

Roche is developing trontinemab, an investigational anti-amyloid antibody, in Phase 3.

Map node for the Brainshuttle amyloid programme on this atlas. Pipeline status is not a recommendation to use an unapproved medicine.

Headquarters

Basel, CH

Scorecard

#4of 5 companies, score 7

0 approved, 1 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.

Type

pharma

Website

Phase 3mAb

Trontinemab is an investigational anti-amyloid antibody in Phase 3. It is not approved and is not for self-administration.

Target
Amyloid-beta
Shares Trontinemab, Alzheimer’s disease and the tag dementia-atlas.
Person
Alois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.
Treatment
Brexpiprazole
Shares Alzheimer’s disease and the tag dementia-atlas.
Collection
ClinicalTrials.gov
Shares Alzheimer’s disease and the tag dementia-atlas.
Treatment
Memantine
Shares Alzheimer’s disease and the tag dementia-atlas.
Institution
National Institute on Aging
Shares Alzheimer’s disease and the tag dementia-atlas.
Technology
CSF amyloid and tau
Shares Alzheimer’s disease and the tag dementia-atlas.
Institution
UCL
Shares Alzheimer’s disease and the tag dementia-atlas.

Phase 3mAb